What is the recommended dosing regimen and key considerations for Paxlovid (nirmatrelvir 300 mg plus ritonavir 100 mg) taken orally twice daily?

Paxlovid Dosing Regimen and Key Considerations

Administer Paxlovid as nirmatrelvir 300 mg (two 150 mg tablets) plus ritonavir 100 mg (one 100 mg tablet) orally twice daily for 5 days, starting within 5 days of symptom onset, with mandatory dose reduction to 150 mg/100 mg twice daily in patients with moderate renal impairment (eGFR 30-59 mL/min). 1

Standard Dosing

The FDA-approved regimen consists of:

• Nirmatrelvir 300 mg + ritonavir 100 mg taken together twice daily (morning and bedtime) for 5 consecutive days 1
• All three tablets must be taken simultaneously
• Can be taken with or without food
• Tablets should be swallowed whole—do not crush, chew, or break 1

Critical Timing Requirements

Initiate treatment as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset, even if baseline symptoms are mild 1. The WHO guidelines strongly recommend this for patients at high risk of hospitalization, as this timing window is essential for efficacy 2.

Renal Dose Adjustments (Mandatory)

Renal function directly impacts nirmatrelvir clearance when co-administered with ritonavir 3. Check eGFR before prescribing:

• Normal/Mild impairment (eGFR ≥60 mL/min): Standard dose 300 mg/100 mg twice daily 1
• Moderate impairment (eGFR 30-59 mL/min): Reduce to 150 mg/100 mg twice daily for all 5 days 1
• Severe impairment (eGFR <30 mL/min):
  • Newer FDA guidance: Day 1: 300 mg/100 mg once, then Days 2-5: 150 mg/100 mg once daily 1
  • Administer after hemodialysis on dialysis days 1

The dose reduction in moderate renal impairment is based on pharmacokinetic data showing 187% increased nirmatrelvir exposure in this population 3.

Hepatic Considerations

• Mild-moderate hepatic impairment (Child-Pugh A-B): No dose adjustment needed 1
• Severe hepatic impairment (Child-Pugh C): Not recommended—no safety data available 1

Drug-Drug Interactions: The Critical Pitfall

Ritonavir is a potent CYP3A4 inhibitor causing extensive drug interactions that persist during treatment and for several days after completion 2, 4. This is the most common reason to avoid Paxlovid.

Management approach:

1. Screen all current medications using the Liverpool COVID-19 Drug Interaction Tool before prescribing 2
2. Contraindicated combinations include drugs primarily metabolized by CYP3A4 where elevated levels cause serious/life-threatening reactions, and strong CYP3A4 inducers that reduce nirmatrelvir efficacy 1
3. For many comedications: Temporarily pause for the 5-day treatment course if clinically safe 4
4. For antiepileptic drugs: Therapeutic drug monitoring and dose adjustment required due to bidirectional interactions 5

The WHO guidelines emphasize that nirmatrelvir/ritonavir should only be used when drug interactions can be appropriately managed 2.

Missed Dose Protocol

• Within 8 hours of scheduled time: Take immediately and resume normal schedule 1
• More than 8 hours late: Skip the missed dose, take next dose at regular time—never double dose 1

Patient Selection

WHO guidelines provide clear risk stratification 2:

• High-risk patients (strong recommendation): Older adults, immunocompromised, significant comorbidities—high certainty evidence of reduced hospitalization and mortality
• Moderate-risk patients (conditional recommendation): Smaller but important reduction in hospitalization risk
• Pregnant/breastfeeding patients: Can be considered despite limited data—no serious adverse reactions reported in WHO Vigibase 2

Common Adverse Effects

Expect diarrhea and dysgeusia (altered taste) more frequently than placebo, but these do not typically lead to treatment discontinuation 2. High certainty evidence shows no increase in adverse effects causing drug discontinuation 2.

Complete the Full Course

Patients must complete all 5 days of treatment to maximize viral clearance and minimize SARS-CoV-2 transmission 1. Even if hospitalized after starting treatment, complete the 5-day course per provider discretion 1.

Key Contraindications

• History of clinically significant hypersensitivity (Stevens-Johnson syndrome, toxic epidermal necrolysis) to nirmatrelvir or ritonavir 1
• Concurrent use of drugs with serious CYP3A4-mediated interactions 1